This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva set to face EU sanction over multiple-sclerosis drug

By Lewis Crofts and Nicholas Hirst ( October 30, 2024, 10:48 GMT | Insight) -- Teva Pharmaceuticals is set to receive a formal penalty from the European Commission as early as this week, as officials wrap up an investigation into the company's use of intellectual property to defend a blockbuster multiple sclerosis drug, MLex has learned. The company was formally accused of antitrust offenses in 2022, which also included claims it was denigrating rival drugs.Teva Pharmaceuticals faces a European Commission antitrust sanction as soon as this week for abusing the market power of its multiple sclerosis drug Copaxone, MLex has learned....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections